[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359411-105":59,"doc-detail-359411-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","safety-and-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with-cancer-and-diabetes","Safety and Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Patients With Cancer and Diabetes","","Diabetes and active cancer frequently coexist, yet evidence for SGLT2 (sodium-glucose cotransporter 2) inhibitor therapy in this high-risk population remains limited. A retrospective single-center study included 849 patients with diabetes and active cancer, comparing SGLT2i-treated patients prior to cancer diagnosis with SGLT2i-naive patients. Over a median 48-month follow-up, SGLT2i use was linked to lower all-cause mortality, though cardiovascular outcomes were higher due to increased heart failure events.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/safety-and-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with-cancer-and-diabetes/359411/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/safety-and-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with-cancer-and-diabetes/359411.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was SGLT2 inhibitor safety and efficacy evaluated in patients with diabetes and cancer?","Question",{"text":112,"@type":113},"The study used a large retrospective single-center cohort of 849 patients with diabetes and active cancer, comparing those treated with SGLT2i before cancer diagnosis versus SGLT2i-naive patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the primary endpoint and what did the results show?",{"text":117,"@type":113},"The primary endpoint was all-cause mortality. Mortality was significantly lower in the SGLT2i group, and multivariable Cox regression identified SGLT2i as an independent predictor of reduced mortality.",{"name":119,"@type":110,"acceptedAnswer":120},"Did SGLT2 inhibitors improve cardiovascular outcomes in this population?",{"text":121,"@type":113},"Cardiovascular outcomes were higher in the SGLT2i group, mainly driven by increased heart failure events. After propensity score matching, cardiovascular outcome differences were not statistically significant.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359411,1790660920,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","Journal of the American Heart Association  \nORIGINAL RESEARCH  \n\n| Safety and Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Patients With Cancer and Diabetes\u003Cbr>Moran Gvili Perelman  , MD; Rafael Y. Brzezinski  , PhD; Shmuel Banai  , MD; Ido Wolf  , MD; Michal Laufer-Perl  , MD, MHA\u003Cbr>BACKGROUND: Diabetes and cancer exhibit a high likelihood of co-occurrence. Diabetes serves as a risk factor for various forms of cancer and is associated with a poorer prognosis. SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) are effective antidiabetic therapies associated with reduced all-cause mortality in the general population; however, data among the population with cancer are scarce. We aimed to assess the safety and efficacy of SGLT2i therapy among patients with diabetes and cancer.\u003Cbr>METHODS: A large retrospective, single-center study including 849 patients diagnosed with diabetes and active cancer. Patients were divided into 2 groups: 169 patients treated with SGLT2i before cancer diagnosis and 680 patients SGLT2i naive. The primary end point was all-cause mortality. The secondary end point was the composite of cardiovascular outcomes, including heart failure, acute coronary syndrome, and arrhythmias.\u003Cbr>RESULTS: After a median follow-up of 48 months (interquartile range, 27–72), all-cause mortality was significantly lower in the SGLT2i group (67% versus 53%, P=0 .001) . Multivariable Cox regression identified SGLT2i as an independent predictor of reduced all-cause mortality (hazard ratio, 0.676 [95% CI, 0.532–0.860], P=0 .001) . Cardiovascular outcomes were higher in the SGLT2i group (28% versus 16%, P=0 .001), driven by increased heart failure events (14% versus 7%, P=0 .008) . After propensity score matching, SGLT2i remained a significant predictor of reduced mortality (P=0 .016), with no significant differences in cardiovascular outcome (P=0 .067) .\u003Cbr>CONCLUSIONS: SGLT2i was associated with lower all-cause mortality in patients diagnosed with diabetes and cancer. Randomized clinical trials are needed to confirm these findings and explore the underlying mechanism.\u003Cbr>Key Words: cancer ■ cardio-oncology ■ cardiotoxicity ■ diabetes ■ SGLT2 |  |  |\n| --- | --- | --- |\n| D | iabetes and cancer frequently co-occur, with up to 18% of patients with cancer also diagnosed with diabetes.1,2 This association is primarily attributed | between diabetes and cancer include hyperinsulinemia, hyperglycemia, and inflammation.3 In vitro studies have demonstrated that insulin promotes tumor cell proliferation,8–10 and elevated plasma insulin levels are independently correlated with an increased risk and accelerated progression of various cancer types.11,12 Moreover, hyperglycemia plays a role in activating inflammatory pathways, fostering angiogenesis, accumulating oncometabolites, disrupting the balance of |\n| to shared risk factors, particularly aging3 and obesity.4 The interplay between these diseases is complex and multifactorial. Diabetes is a well-established risk factor for several malignancies5 and is linked to poorer response to cancer therapies6 and reduced survival.7 Potential mechanisms underlying the relationship |  |  |\n\nCorrespondence to: Michal Laufer-Perl, MD, MHA, FESC, FHFA, Department of Cardiology, Tel Aviv Medical Center, 6 Weizmann Street, Tel Aviv, Israel.  \n[Email:](Email: michalpela@gmail.com)[ michalpela@gmail.com](Email: michalpela@gmail.com)  \nThis article was sent to Julie K. Freed, MD, PhD, Senior Associate Editor, for review by expert referees, editorial decision, and final disposition. Supplemental Material is available at [https://www.ahajournals.org/doi/suppl/10.1161/JAHA.125.042404](https://www.ahajournals.org/doi/suppl/10.1161/JAHA.125.042404)[ ](https://www.ahajournals.org/doi/suppl/10.1161/JAHA.125.042404)[For Sources of Funding and Disclosures](For Sources of Funding and Disclosures) , see page 9.  \n© 2026 The Author(s) . Published on behalf of the American Heart Association, Inc. , by Wi","cbCaigOVfNK1Hpfn","https://ap.wps.com/l/cbCaigOVfNK1Hpfn","pdf",1227068,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Clinical Perspective\n## What Is New?\n## Clinical Implications","[{\"question\":\"How was SGLT2 inhibitor safety and efficacy evaluated in patients with diabetes and cancer?\",\"answer\":\"The study used a large retrospective single-center cohort of 849 patients with diabetes and active cancer, comparing those treated with SGLT2i before cancer diagnosis versus SGLT2i-naive patients.\"},{\"question\":\"What was the primary endpoint and what did the results show?\",\"answer\":\"The primary endpoint was all-cause mortality. Mortality was significantly lower in the SGLT2i group, and multivariable Cox regression identified SGLT2i as an independent predictor of reduced mortality.\"},{\"question\":\"Did SGLT2 inhibitors improve cardiovascular outcomes in this population?\",\"answer\":\"Cardiovascular outcomes were higher in the SGLT2i group, mainly driven by increased heart failure events. After propensity score matching, cardiovascular outcome differences were not statistically significant.\"}]","Safety and Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Patients With Cancer and Diabetes | PDF",1790136846,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f099bc70ccaf085e200789dfcafb96c2.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db24e421bf29875f1aede45557dc502e.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05e14e2de0e05687b761d35052699d24.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a0f41f77b1b1c998787039b1f18b37f.webp",980,1287]